NCT03747159View on ClinicalTrials.gov

Synergetic B-cell Immunomodulation in SLE - 2nd Study.

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

October 1, 2018

Primary Completion Date

June 7, 2024

Study Completion Date

June 7, 2026

Conditions
Lupus Erythematosus, Systemic
Interventions
DRUG

Belimumab Injection

Weekly injection of belimumab prior to two infusions of rituximab with continuation of the belimumab as maintenance therapy

Trial Locations (4)

9713 GZ

University Medical Center Groningen, Groningen

2333 ZC

Leiden University Medical Center, Leiden

6525 GA

Radboud University Medical Center, Nijmegen

2545 AA

HagaZiekenhuis, The Hague

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

Dutch Kidney Foundation

OTHER

collaborator

GlaxoSmithKline

INDUSTRY

lead

Leiden University Medical Center

OTHER

NCT03747159 - Synergetic B-cell Immunomodulation in SLE - 2nd Study. | Biotech Hunter | Biotech Hunter